摘要
目的 评价高通量血液透析(HFHD)联合低钙透析液对终末期肾病(ESRD)合并皮肤瘙痒患者皮肤瘙痒及睡眠质量的影响。方法 选择76例ESRD合并皮肤瘙痒患者为研究对象,随机分为研究组(n=38)与对照组(n=38)。对照组采用HFHD与正常钙透析液进行透析,研究组采用HFHD联合低钙透析液进行透析。比较两组皮肤瘙痒情况(皮肤瘙痒程度、范围评分)、实验室指标[血清甲状旁腺激素(PTH)、血钙及血磷]、睡眠质量[匹兹堡睡眠质量指数量表(PSQI)评分与睡眠障碍发生率]。结果 研究组与对照组治疗前皮肤瘙痒程度、范围评分均无统计学差异(P>0.05);治疗8周后,两组皮肤瘙痒程度、范围评分较治疗前显著降低,研究组皮肤瘙痒程度评分(1.4±0.6)分、皮肤瘙痒范围评分(1.5±0.6)分低于对照组的(2.1±1.0)、(2.3±1.1)分(P<0.05)。研究组与对照组治疗前血清PTH、血钙及血磷均无统计学差异(P>0.05);两组治疗8周后血清PTH、血磷水平较治疗前均显著降低,研究组血清PTH(265.4±54.2)pg/ml、血磷(1.5±0.4)mmol/L显著低于对照组的(294.9±62.7)pg/ml、(1.8±0.6)mmol/L(P<0.05);研究组治疗8周后血钙(2.1±0.3)mmol/L较治疗前的(2.5±0.3)mmol/L降低(P<0.05),但两组治疗8周后血钙水平无统计学差异(P>0.05)。研究组与对照组治疗前PSQI评分与睡眠障碍发生率无统计学差异(P>0.05)。治疗8周后,两组的PSQI评分与睡眠障碍发生率均较治疗前降低,研究组PSQI评分(5.8±2.7)分与睡眠障碍发生率26.3%均低于对照组的(9.2±3.5)分、50.0%(P<0.05)。结论 HFHD联合低钙透析液可改善ESRD合并皮肤瘙痒患者皮肤瘙痒与睡眠质量。
Objective To evaluate the effect of high flux hemodialysis(HFHD)combined with low calcium dialysate on skin pruritus and sleep quality in patients with end-stage renal disease(ESRD)complicated with skin pruritus.Methods 76 ESRD patients complicated with skin pruritus were enrolled and randomly divided into a study group(n=38)and a control group(n=38).The control group received HFHD and normal calcium dialysate,while the study group received HFHD combined with low calcium dialysate.Both groups were compared in terms of skin itching(scores for skin itching severity and range),laboratory indexes[serum parathyroid hormone(PTH),blood calcium,blood phosphorus],and sleep quality[Pittsburgh Sleep Quality Index Scale(PSQI)score and incidence of sleep disorders].Results Before treatment,there was no statistical difference in scores for skin itching severity and range between the study group and the control group(P>0.05).After 8 weeks of treatment,the scores for skin itching severity and range in the two groups were significantly lower than those before treatment;the scores for skin itching severity and range in the study group were(1.4±0.6)and(1.5±0.6)points,which were lower than(2.1±1.0)and(2.3±1.1)points in the control group(P<0.05).Before treatment,there were no significant differences in serum PTH,serum calcium and serum phosphorus between the study group and the control group(P>0.05).After 8 weeks of treatment,the serum PTH and blood phosphorus levels in both groups were significantly lower than those before treatment;the study group had serum PTH of(265.4±54.2)pg/ml and blood phosphorus of(1.5±0.4)mmol/L,which were significantly lower than(294.9±62.7)pg/ml and(1.8±0.6)mmol/L in the control group(P<0.05).The serum calcium level of the study group was(2.1±0.3)mmol/L after 8 weeks of treatment,which was lower than(2.5±0.3)mmol/L before treatment(P<0.05),but there was no significant difference between the two groups after 8 weeks of treatment(P>0.05).Before treatment,there was no significant difference in the P
作者
陈森兰
CHEN Sen-lan(Hemodialysis Department,Quanzhou First Hospital,Quanzhou 362000,China)
出处
《中国现代药物应用》
2024年第18期14-17,共4页
Chinese Journal of Modern Drug Application
关键词
终末期肾病
皮肤瘙痒
维持性血液透析
高通量血液透析
低钙透析液
睡眠障碍
End-stage renal disease
Skin pruritus
Maintenance hemodialysis
High flux hemodialysis
Low calcium dialysate
Sleep disorders
